61
Participants
Start Date
May 2, 2018
Primary Completion Date
February 9, 2023
Study Completion Date
February 9, 2023
Avelumab (MSB0010718C)
IV treatment: Avelumab administered at 800 mg IV every two weeks
Axitinib (AG-013736)
Oral treatment: Axitinib given 5 mg PO BID
National Cheng Kung University Hospital, Tainan City
National Cancer Center, Goyang-si
Consorcio Hospitalario Provincial de Castellon, Castellon
Seoul National University Bundang Hospital, Seongnam-si
Saint Francis Hospital, Greenville
Saint Francis Hospital Cancer Center, Greenville
Oncology Hematology Associates, Springfield
Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha
Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha
Chi Mei Hospital, Liouying, Tainan City
Arizona Oncology Associates- Biltmore Cancer Center, Phoenix
Arizona Oncology Associates- Deer Valley Cancer Center, Phoenix
Arizona Oncology Associates- East Valley Cancer Center, Tempe
Arizona Oncology Associates- Saguaro Cancer Center, Glendale
Arizona Oncology Associates, Goodyear
The Oncology Institute of Hope and Innovation, Whittier
The Oncology Institute of Hope and Innovation, Long Beach
The Oncology Institute of Hope and Innovation, Glendale
The Oncology Institute of Hope and Innovation, Santa Ana
"LLC University clinic of headache", Moscow
"Limited Liability Company VitaMed (LLC VitaMed)", Moscow
"LLC University Clinic of Headache", Moscow
"Limited Liability Company VitaMed (LLC VitaMed)", Moscow
"GBUZ of Stavropol Territory Pyatigorsk Inter-regional Oncology Dispanser", Pyatigorsk
Bacs-Kiskun Megyei Korhaz Onkoradiologiai Kozpont, Kecskemét
Pecsi Tudomanyegyetem Klinikai Kozpont, Pécs
Tudogyogyintezet Torokbalint, Törökbálint
Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma
Cardiologia - Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma
Farmacia Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma
UOC di Radiologia - Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie, Warsaw
Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie w Warszawie, Warsaw
Regionalny Szpital Specjalistyczny Im. Dr. Wladyslawa Bieganskiego w Grudziadzu, Grudziądz
Centrum Medyczne Dom Lekarski S.A., Szczecin
Samsung Medical Center, Gangnam-gu
Asan Medical Center, Songpa-gu
Severance Hospital, Yonsei University Health System, Seoul
Instituto Catalan de Oncologia, L'Hospitalet de Llobregat
Lead Sponsor
Pfizer
INDUSTRY